Publications by authors named "S Sarrou"
Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no biologics on presumed hepatic steatosis in patients with IBD.
View Article and Find Full Text PDFArticle Synopsis
- Predominantly antibody deficiencies (PAD) are the most common type of immune problems in people, but it's not well-known how many people have them in Greece.
- A study was done on 153 patients to learn more about these deficiencies, and they found different types of PAD among the patients.
- The study showed that it often took a long time (about 9 years) for people to be diagnosed with PAD after they first noticed symptoms, and many of the patients had more serious health issues like infections and even cancer.
Patients with predominantly antibody deficiencies (PADs) display hypogammaglobulinemia with a high prevalence of infections, along with autoimmune manifestations, benign and malignant lymphoproliferation and granulomatous disease. It is noteworthy that PAD patients, even those with defects in the same causative genes, display a variable clinical phenotype, suggesting that additional genetic polymorphisms, located in either immune-related or non-immune-related genes, may affect their clinical and laboratory phenotype. In this context, we analyzed 80 PAD patients, including 70 with common variable immunodeficiency (CVID) for defects, in order to investigate the possible contribution to PAD clinical phenotype.
View Article and Find Full Text PDFDuring the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities).
View Article and Find Full Text PDFArticle Synopsis
- * A study involving 249 participants classified them based on the WHO clinical progression scale, highlighting that elderly patients with comorbidities were more likely to develop severe respiratory issues.
- * Certain genetic polymorphisms (-rs1834481, -rs5743708, and -rs4986791) were identified as independent risk factors, suggesting they could serve as molecular predictors for the severity of COVID-19 in infected individuals.